Circulating Tumor Cells (CTC) Liquid Biopsy market analysis report is a careful investigation of current scenario of the market and future estimations which spans several market dynamics. This market report presents the best market and business solutions to Medical Devices industry in this rapidly revolutionizing market place to thrive in the market. Market definition gives the scope of particular product with respect to the driving factors and restraints in the market. Competitor strategies such as new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions can be utilized well by the Medical Devices industry to take better steps for selling goods and services.
Data Bridge Market Research analyses that the circulating tumor cells (CTC) liquid biopsy market which was USD 1,173.84 million in 2022, is expected to reach USD 4,170.06 million by 2030, growing at a CAGR of 17.17% during the forecast period of 2023 to 2030.
Download Exclusive Sample (350 Pages PDF) Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-circulating-tumor-cells-ctc-liquid-biopsy-market
The liquid biopsy is a type of non-invasive blood test which identifies circulating tumor cells and tumor DNA fragments which are released in the blood by primary tumors and metastatic sites. It is an alternative to surgical biopsy procedure, and it allows surgeon to detect cancer at a very early stage. The circulating tumor cells function as a seed of metastases. The patients who have developed solid tumors it is found in them. The detection and quantification of tumor cells in the blood of cancer patients is allowed by the testing of circulating tumor cells. There are various types of biological phenotypes of circulating tumor cells (CTCs) such as stem cell-like or mixed, mesenchymal or epithelial. These phenotypes are present in blood in a very small quantity and due to which, a phase of isolation-enrichment is required in their detection.
Global Circulating Tumor Cells (CTC) Liquid Biopsy Dynamics
Drivers
- Rising prevalence of cancer
The rising prevalence of different types of cancer is boosting the market’s growth. The increasing number of cancer cases across the world is fuelling the demand of liquid biopsy. Breast cancer was the most common cancer 2020 with 2.26 million cases and further lung cancer with 2.21 million cases. The rising prevalence of cancer can be reduced through early detection of cancer and appropriate treatment. Circulating cancer cells are suitable for developing preclinical models, particularly 3D organoid cultures, for use in drug screening, disease modelling, genome editing, and organoid biobanks, thus significantly driving the market’s growth.
- Awareness initiatives by global health organizations and government
The governments in various countries and global health organizations are spreading awareness about cancer and other growing diseases. National Cancer Control program of WHO, is a public health program aiming to reduce the growing number of cancer deaths and improve the life of cancer patients. Furthermore, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), initiated by the US Centers for Diseases and Prevention (CDC) in 1991, provides breast cancer screening and diagnosis for uninsured and low-income patients in the US every year. The rising awareness in people about the effects and necessity to cure the diseases is increasing the liquid biopsy tests and treatments further driving the market’s growth.
Some of the major players operating in the circulating tumor cells (CTC) liquid biopsy market are:
- QIAGEN (Germany)
- Bio-Techne (U.S.)
- Precision Medical Group, LLC. (U.S.)
- Aviva Systems Biological Corporation (U.S.)
- Biocept, Inc. (U.S.)
- Fluxion Biosciences, Inc. (U.S.)
- Greiner Bio-One International GmbH (Austria)
- Ikonisys (U.S.)
- Miltenyi Biotec (Germany)
- IVDiagnostics (U.S.)
- BioFluidica (U.S.)
- Canopus Medical (Sweden)
- Biolidics Limited (Singapore)
Browse Full Report Along With Facts and Figures @ https://www.databridgemarketresearch.com/reports/global-circulating-tumor-cells-ctc-liquid-biopsy-market
Browse Trending Reports:
About Data Bridge Market Research:
An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune.
Data Bridge Market Research has more than 500 analysts working in different industries. We have served more than 40% of the Fortune 500 companies globally and have a network of more than 5,000 clients worldwide. Data Bridge is an expert in creating satisfied customers who trust our services and trust our hard work with certainty. We are pleased with our glorious 99.9% customer satisfaction rating.
Contact Us: -
Data Bridge Market Research
US: +1 888 387 2818
United Kingdom: +44 208 089 1725
Hong Kong: +852 8192 7475
